Too High of a Dosage of GLP-1 Drugs Possibly Cause Personality Changes Reported

The Today Show recently reported on a phenomenon some patients call “Ozempic personality” — a set of personality and emotional changes linked to GLP-1 weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.

What people are experiencing

Change	Description
Anhedonia	Loss of pleasure, joy, or enthusiasm for activities previously enjoyed (dining out, socializing, hobbies)
Emotional numbness	Feeling like “the lights had dimmed” — flat emotions, reduced excitement
Reduced motivation	Less drive to exercise, get out of bed, or pursue interests
Less pleasure-seeking	Actively seeking less pleasure from activities once loved

One patient, Dave Knapp (host of the “On The Pen” podcast about GLP-1s), reported after starting Mounjaro: “I realized that I wasn’t experiencing the same level of enjoyment or actively seeking out pleasure from activities I once loved. Many things that used to excite me no longer drew my attention”.

What experts say

Expert	Key Points
Dr. Christopher McGowan (obesity medicine expert, North Carolina)	Identified this as anhedonia; says “This is not just a psychological issue; we are genuinely hearing these reports from patients”
FDA	Currently evaluating reports of mood changes; preliminary evaluation found no clear link to suicidal thoughts, but continues monitoring

• Not officially listed: Anhedonia is not among the officially listed side effects for Ozempic, Wegovy, Mounjaro, or Zepbound
• Not common: Dr. McGowan notes it’s not common; many patients report positive outcomes like enhanced mood, confidence, and energy
• Anecdotal only: Reports are largely anecdotal and haven’t been specifically studied in clinical trials

Why this might happen

GLP-1 medications work by:

• Influencing brain receptors associated with hunger and reward
• Altering food’s appeal to facilitate weight loss
• Since food is linked to comfort, celebration, and social interaction, changes in food interest can affect emotional well-being

What to do if you experience this

Doctors recommend:

1. Talk to your healthcare provider if you notice emotional changes
2. Dosage adjustment or switching to a different GLP-1 may help
3. Dave Knapp now takes Zepbound at a lower dose, which controls appetite without diminishing his exercise drive
4. Don’t stop medication without consulting your doctor
5. Pay attention if loved ones say you seem less motivated

Warning signs Dr. McGowan highlighted: difficulty getting out of bed, lacking energy to start the day, or not enjoying daily experiences.

The Today Show segment aired on May 19, 2026, with NBC’s Anne Thompson reporting.

---

1 Biological mechanisms linking GLP-1 receptors to the brain reward system
2 Comparing reported anhedonia to known side effects of antidepressant drugs
3 Expert strategies for managing emotional flattening while on GLP-1s

1. Biological Mechanisms Linking GLP-1 Receptors to the Brain Reward System

Key anatomical pathways

Brain Region	GLP-1 Receptor Location	Function in Reward
Ventral Tegmental Area (VTA)	High expression on dopamine neurons	Core reward center; projects to nucleus accumbens
Nucleus Accumbens (NAc)	GLP-1Rs on medium spiny neurons	Processes reward and motivation; reduced food craving here
Lateral Septum (LS)	Highest GLP-1R expression in brain (GABAergic neurons)	Modulates dopamine uptake and cocaine reward
Nucleus Tractus Solitarius (NTS)	GLP-1 neurons project from here	Direct projections to reward areas; crosses blood-brain barrier
Orbitofrontal Cortex (OFC)	Increased activity with GLP-1	Regulates food consumption decisions
Insula	Decreased activity to food anticipation	Reduces food cravings

GLP-1 can cross the blood-brain barrier and is also produced by neurons and microglial cells within the brain.

Dopamine modulation mechanisms

$$\text{GLP-1}\to \text{increases DA uptake, DA clearance, DAT surface expression in striatum}$$GLP-1→increases DA uptake, DA clearance, DAT surface expression in striatum

• GLP-1 increases dopamine uptake and clearance in the striatum, reducing phasic dopamine signaling
• GLP-1 antagonist reduced lithium chloride–induced suppression of NAc phasic dopamine release
• In VTA, GLP-1 suppresses AMPA-R–mediated excitatory postsynaptic potentials on dopamine neurons

Glutamatergic neurotransmission

Effect	Mechanism
Increased sEPSC frequency in NAc	Presynaptic GLP-1R activation on glutamatergic terminals
Decreased paired-pulse ratio	Increased probability of glutamate release
Suppressed AP firing in PVT→NAc neurons	Glutamate and GABA receptor–dependent

Human fMRI findings

• Exenatide (GLP-1 agonist) decreased brain responses to anticipation of palatable food in the left insula
• Increased activity to consumption of food in the right OFC and left insula
• Reduced activation in bilateral insula, left putamen, right OFC to both food and high-cue stimuli

Reward system effects beyond food

GLP-1 reduces use of:

• Cocaine (reduced CPP, self-administration, dopamine release in striatum)
• Alcohol (reduced intake, seeking, accumbal dopamine)
• Nicotine (blocked CPP, reduced intake)
• Amphetamine (reduced hyperlocomotion, CPP)

This explains why GLP-1s can reduce pleasure from food and potentially other rewards — they dampen the mesolimbic dopamine pathway broadly.

---

2. Comparing GLP-1–Induced Anhedonia to Antidepressant-Induced Emotional Blunting

Key differences and similarities

Feature	GLP-1–Induced Anhedonia	Antidepressant-Induced Emotional Blunting
Primary symptom	Loss of pleasure/joy (especially food-related)	Numbing of both positive and negative emotions
Definition	Diminished interest/pleasure in activities (DSM-5 anhedonia)	Reduction in intensity/frequency of love, affection, fear, anger
Prevalence	Anecdotal reports; not officially listed as side effect	40–60% of SSRI/SNRI patients
Neurotransmitter	Dopamine reduction in mesolimbic pathway	Serotonin ↑ → inhibits dopamine in prefrontal cortex
Mechanism	Direct GLP-1R activation in VTA/NAc → reduced dopamine signaling	SSRIs increase 5-HT → suppress midbrain DA systems
Dose relationship	Lower doses may improve symptoms	Higher doses more likely to cause blunting
Both positive & negative emotions	Primarily positive (pleasure, joy)	Both positive and negative diminished
Motivation	Reduced drive/excitement	Distinguished from apathy (lack of motivation)

Neuropsychological mechanisms comparison

Antidepressants (SSRIs):

$$\text{SSRI}\to \uparrow 5\text{-HT}\to \downarrow \text{DA in prefrontal cortex}\to \text{emotional blunting}$$SSRI→↑5-HT→↓DA in prefrontal cortex→emotional blunting

• SSRIs increase serotonin, which inhibits midbrain dopamine systems
• Reduces prefrontal cortex activation to both rewarding and aversive stimuli

GLP-1 Agonists:

$$\text{GLP-1}\to \text{GLP-1R in VTA/NAc}\to \uparrow \text{DA uptake/clearance}\to \downarrow \text{phasic DA signaling}$$GLP-1→GLP-1R in VTA/NAc→↑DA uptake/clearance→↓phasic DA signaling

• Direct action on reward circuit → reduced dopamine availability
• More specific to reward/pleasure than general emotional numbing

Clinical distinction

• Anhedonia (GLP-1): “I don’t enjoy things I used to”
• Emotional blunting (antidepressants): “I can’t feel strongly about anything — not happy, not sad”

---

3. Expert Strategies for Managing Emotional Flattening While on GLP-1s

Medical/pharmacological strategies

Strategy	Details	Evidence
Dose adjustment	Lower dose may reduce emotional flatness while maintaining appetite control	Dave Knapp switched to lower-dose Zepbound successfully
Switch GLP-1 medication	Try different GLP-1 (e.g., semaglutide → tirzepatide)	Individual responses vary
Gradual titration	Start slow with dose changes to reduce transient mood shifts	Reduces side effects that provoke mood changes
Monitor for depression	Anhedonia is core symptom of depression; seek evaluation if persistent	Red-flag: symptoms >2 weeks

Behavioral/nutritional strategies

Strategy	Implementation
Daily mood tracking	Rate mood 1–10; note triggers, appetite, sleep, medication timing
Weekly emotional summary	Record patterns (irritability, energy, low mood)
Optimize nutrition	Ensure adequate protein, calories, B12, D, folate, iron
Maintain routine	Regular sleep, scheduled meals, light exercise, consistent dosing
Build new pleasure sources	If food was primary reward, cultivate exercise, hobbies, social connection
Side-effect log	Note nausea, dizziness, constipation, sleep disruption (often precede emotional changes)

Psychological/emotional regulation tools

Tool	Technique
5-4-3-2-1 Grounding	5 things you see, 4 touch, 3 hear, 2 smell, 1 taste
Mood Bridging Exercise	Rate morning mood, set target emotion (joy/calm), reflect evening on matching moments
Emotional Weather Report	Describe state like weather: cloudy? stormy? hot (angry)/cold (numb)/warm (content)?
Journaling	Track mood, sleep, daily routines; identify supportive patterns
Mindfulness/CBT	Cognitive-behavioral techniques help process identity changes
Body neutrality	Focus on what body allows you to do, not appearance

Social/identity strategies

Strategy	Example
Open communication	“I’m eating less but still want to enjoy time together”
Find non-food activities	“Let’s find activities we can do that aren’t centered around food”
Support groups	Share experiences with friends, family, or GLP-1 support groups
Curate social media	Follow body-positive, body-diverse voices
Set boundaries	Redirect focus to how you feel rather than how you look

When to contact a provider

Seek prompt medical attention for:

• Persistent depressed mood or suicidal thoughts
• Emotional blunting interfering with daily life >2 weeks
• Severe anxiety, panic attacks, or intrusive thoughts
• Severe sleep disturbance or cognitive changes

Expert recommendation summary

Dr. Christopher McGowan (obesity medicine expert):

• “This is not just a psychological issue; we are genuinely hearing these reports from patients”
• Watch for: difficulty getting out of bed, lacking energy, not enjoying daily experiences

David Osuji, PMHNP (psychiatrist):

• “If any emotional symptom lasts longer than 2 weeks, contact your provider—don’t wait”
• Weekly mood tracking + monthly provider check-ins recommended

---

The key takeaway: GLP-1–induced anhedonia shares features with antidepressant emotional blunting but appears more reward-specific (especially food-related) and may be dose-dependent. Management involves dose adjustment, behavioral strategies, and open communication with your prescriber.

---

What the Today Show discussed applies to the entire GLP-1 drug class, including Zepbound. Here’s the breakdown:

What Zepbound is vs. what causes the personality changes

Aspect	Zepbound (tirzepatide)
Drug class	Dual agonist: GIP + GLP-1 receptors
GLP-1 component	Yes — activates GLP-1 receptors in the brain’s reward system
GIP component	Yes — also activates GIP receptors (makes it more potent for weight loss)
Anhedonia risk	Yes — same mechanism as other GLP-1s because it activates GLP-1 receptors
FDA label	Includes warning to monitor for depression and suicidal thoughts

Key facts about Zepbound and emotional changes

Fact	Details
Clinical trials	Pivotal SURMOUNT trials did not find mood disorders at higher rates than placebo
Mood side effects in trials	Less than 1% — similar to placebo
Official side effect	Anhedonia is not officially listed on FDA label, but patients report it
Anecdotal reports	Some patients report anhedonia, emotional blunting, anxiety, depression
Mechanism	GLP-1 component activates reward circuit → reduces dopamine signaling (same as Ozempic/Wegovy)

The patient example from Today Show

The patient Dave Knapp (podcast host) who reported “Ozempic personality” actually switched to Zepbound and found:

• Lower-dose Zepbound controlled his appetite without diminishing his exercise drive
• This suggests the effect may be dose-dependent and varies by individual

Bottom line

Yes, Zepbound can potentially cause the same personality/emotional changes discussed on Today because:

1. It contains a GLP-1 agonist component that activates the same brain reward pathways
2. The mechanism affecting dopamine and anhedonia is the same GLP-1 pathway
3. Patient reports of emotional blunting exist for Zepbound specifically

However:

• It’s not common (under 1% in trials)
• Not everyone experiences it — many report improved mood from weight loss
• Lower doses may reduce risk while still working for appetite control